The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

11 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-05-31

Study Completion Date

2018-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical trial is testing the safety, tolerability and effectiveness of NVX-108 administered via intravenous infusion in combination with standard radiation and chemotherapy.

NVX-108 is being developed to increase the amount of oxygen delivered to tumors which is hoped to increase the effectiveness of radiation therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM

NCT03862430

Glioblastoma Multiforme

ACTIVE_NOT_RECRUITING PHASE2

Reirradiation and Niraparib in Patients With Recurrent Glioblastoma

NCT05666349

Recurrent Glioblastoma

WITHDRAWN PHASE1

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

NCT07215910

Astrocytoma, IDH-Mutant, Grade 3

NOT_YET_RECRUITING PHASE3

ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00770471

Brain and Central Nervous System Tumors

COMPLETED PHASE1

Study of Vioxx and Radiation Therapy for Brainstem Glioma

NCT00038389

Glioma Brain Neoplasms

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glioblastoma Multiforme

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dose Escalation

NVX-108 (DDFP liquid emulsion) i.v. in conjunction with Radiation Treatment and Temozolimide. 0.05-0.35cc/kg.

Group Type EXPERIMENTAL

NVX-108

Intervention Type DRUG

0.2% emulsion administered i.v.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NVX-108

0.2% emulsion administered i.v.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Dodecafluoropentane

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Histologically-confirmed newly-diagnosed glioblastoma multiforme.
2. No prior treatment for glioblastoma apart from surgical resection.
3. No prior treatment for glioblastoma apart from surgical resection.
4. Planned for 60 Gray of focal radiation administered in 30 fractions, concurrently with temozolomide chemotherapy.
5. Manageable risks associated with potential radiation necrosis in the radiation field, based on size of the field and proximity to eloquent brain regions (as assessed by the investigator).
6. Aged 18-70 years.
7. ECOG performance status 0-2.
8. Life expectancy of at least 3 months.
9. If receiving glucocorticoid therapy, the dose must be stable over at least 7 days prior to study enrollment.
10. Archived tumor tissue available for central review.
11. Able to undergo gadolinium-enhanced MRI (Gd-MRI) scans.
12. Baseline MRI performed within 14 days before starting study treatment, while on a stable glucocorticoid dose for at least 5 days before and during the imaging study.
13. Adequate hematologic, renal and hepatic function, as defined by:

Absolute neutrophil count (ANC) ≥ 1.5 109/L Platelet count ≥ 100 109/L Hemoglobin ≥ 90 g/L International normalized ratio (INR) and activated partial thromboplastin time (APTT) \< 1.5 upper limit of normal (ULN) Plasma creatinine\< 1.5 ULN Total bilirubin within normal limits (\< 2.5 ULN if Gilbert's syndrome) AST and ALT \< 2.5 ULN
14. Patients who are women of childbearing potential or men (unless vasectomised) must agree to use a highly-effective method of birth control, such as hormonal contraceptive implants, combined oral contraceptives, an intrauterine device, a double-barrier method (eg. condom with a diaphragm) or abstinence, from study entry until 4 months after completing study therapy. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
15. Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

1. Presence of leptomeningeal disease or multifocal glioblastoma that cannot be encompassed within a feasible and safe radiation field.
2. Intracranial bleeding, except for stable grade 1 hemorrhage.
3. Has not recovered from the adverse effects of surgical resection or biopsy, except for neurological deficits.
4. Patients who have received any other investigational agent within 4 weeks before enrollment.
5. Stroke or transient ischemic attack within 6 months before enrollment.
6. Myocardial infarction within 6 months before enrollment, unstable angina, New York Heart Association class II or greater congestive heart failure, or uncontrolled hypertension (systolic BP \> 160 mmHg and/or diastolic BP \> 100 mmHg).
7. Congenital long QT syndrome.
8. Clinically-significant chronic obstructive pulmonary disease or asthma.
9. Active major infection requiring treatment.
10. A history of other malignancies, except adequately treated non-melanoma skin cancer, curatively treated in-situ cancer or other solid tumors curatively treated with no evidence of disease for ≥ 2 years.
11. Known infection with human immunodeficiency virus or hepatitis B or C virus.
12. Current anticoagulant or antiplatelet therapy, except for prophylactic doses of low molecular weight heparins or low-dose aspirin.
13. History of allergic reactions attributed to compounds of similar chemical composition to NVX-108.
14. Women who are pregnant or breast feeding.
15. Inability to comply with study procedures.
16. History or evidence of any other clinically-significant condition that, in the opinion of the investigator, would pose a risk to subject safety or interfere with study procedures, evaluation or completion.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No